Synovate Healthcare launches Hyperlipidemia Monitor in Asia-Pacific

Synovate Healthcare, the health care specialist unit of market research firm Synovate, says it has launched its newest syndicated therapy monitor focusing on the drug treatment of patients with hyperlipidemia in Asia-Pacific. Hyperlipidemia, a condition of abnormally high blood lipid levels, is closely associated with a significant increase in the risk of cardiovascular disease.

“Our new hyperlipidemia monitor further strengthens Synovate Healthcare’s extensive syndicated products in the region, and also complements our diabetes monitor, which we launched in Asia in 2006,” said Pieter De Richter, vice president of Global Therapy Monitors for Synovate Healthcare.

The prevalence of hyperlipidemia in Asia has been rising with changing lifestyles and, while statins continue to be the cornerstone of treatment, a number of new medications to treat the condition are currently in development. The results from the first wave of Synovate’s hyperlipidemia monitor in China, conducted in 4th quarter 2010, show that as many as 43% of Chinese patients on hypolipemics have concomitant type 2 Diabetes. As hyperlipidemia rarely occurs in isolation and is usually part of a complex set of metabolic and cardiovascular disorders, 59% of Chinese patients on hypolipemics are also suffering from hypertension.